Form 4 for ENTX Entera Bio Ltd.

Accepted 2024-08-02 00:00:00 ET · period of report 2024-07-31 · accession 0001178913-24-002391 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2024-08-02	2024-07-31	ENTX	Toledano Miranda Jayne	CEO, Dir	A - Grant	$0.00	+124.1K	234.9K	+112%	$0
D	2024-08-02	2024-07-31	ENTX	Toledano Miranda Jayne	CEO, Dir	A - Grant	$0.00	+500.0K	500.0K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Ordinary Shares, par value NIS 0.0000769 per share	2024-07-31	A	A	124,121	$0.00	234,873	D	—	—	(F1) Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on April 19, 2024, subject to approval by the Company's shareholders, which was obtained on July 31, 2024. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on April 19, 2024.
2	Derivative	Stock Option (Right to Buy)	2024-07-31	A	A	500,000	$0.00	500,000	D	$1.99 · — to 2034-04-19	500,000 Ordinary Shares, par value NIS 0.0000769 per share	(F2) This grant of options was approved by the Board on April 19, 2024, subject to approval by the Company's shareholders, which was obtained on July 31, 2024. The options vest over a three-year period that commenced on April 19, 2024, with a third of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining two-year period.